Early and late hematologic toxicity following CD19 CAR-T cells
Author:
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Link
http://www.nature.com/articles/s41409-019-0487-3.pdf
Reference31 articles.
1. June CH, Sadelain M. Chimeric Antigen receptor therapy. N Engl J Med. 2018;379:64–73.
2. Salter AI, Pont MJ, Riddell SR. Chimeric antigen receptor modified T cells: CD19 and the road beyond. Blood. 2018;131:2621–9.
3. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118:4817–28.
4. Turtle CJ, Riddell SR, Maloney DG, Turtle CJ, Hanafi L, Berger C, et al. CD19 CAR–T cells of defined CD4+ :CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126:2123–38.
5. Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent to treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129:3322–31.
Cited by 253 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies;Annals of Laboratory Medicine;2024-01-11
2. Improving the safety of CAR‐T‐cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B‐cell lymphoma undergoing CAR‐T‐cell therapy;American Journal of Hematology;2024-01-10
3. Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia;2024-01-02
4. Miscellaneous Complications of Chimeric Antigen Receptor T-Cell Therapy;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024
5. Chimeric Antigen Receptor T-Cell Therapy in Acute Lymphoblastic Leukemia;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3